Early Access Programs
Accelerating Patient Access
Make a drug available in a country ahead of marketing approval and commercialization so patients can benefit sooner.
Our Medicine Access Programs
Compassionate Use
Early Access Programs
Post Trial Supply
Named Patient Sales
Market Withdrawals
Tender Supply
Medical Crisis
Market Shortages
Global Donation Programs
US Expanded Access
Global Access, Delivered with Purpose.
Early Access Programs (EAPs), also known as managed access programs (MAPs) or Expanded Access Programs,offer a compliant pathway for pharmaceutical and biopharmaceutical manufacturers to provide investigational or unlicensed therapies to patients with serious or life-threatening conditions before commercial approval. These programs expand access while producing actionable data that support regulatory strategy, market access planning, and launch preparation.
Accelerate Patient Access.
Generate Real-World Insight.
Strengthen Launch Readiness.
When to use an Early Access Program
When safety/efficacy is established.
In Phase II and III
To meet urgent patient need.
Pre-approval
Where an unmet medical need is.
In rare diseases
To support access in markets awaiting regulatory decisions.
Post-first approval
Core capabilities.
-
A dedicated Program Manager oversees all day-to-day operations, timelines, stakeholder communications, and risk mitigation while our US and EU-based Customer Advocates serve as the primary POC for Tanner customers, pharmacists and physicians.
-
We design compliant protocols tailored to country requirements, manage regulatory submissions, and support approvals across global health authorities.
Learn more.
-
We provide strategic guidance on and compliant execution of program awareness practices to ensure that healthcare providers, healthcare systems, and eligible patients can appropriately discover and access your program.
How we deliver
Trusted partners to:
Novartis ~ Amgen ~ Albireo ~ Endo ~ Pfizer ~
Novartis ~ Amgen ~ Albireo ~ Endo ~ Pfizer ~
Why Manufacturers Choose Tanner
Where others deliver access, Tanner delivers impact.
Common Challenges Teams Face in Access Programs
1. Slow, reactive activation
Projects lose momentum because partners are slow to mobilise and operate transactionally.
2. Limited strategic and therapeutic depth
Support focuses on operations, without the strategic insight or rare-disease expertise high-stakes programmes demand.
3. Insufficient global capability
Gaps in international reach and country pathways create risk, delays, and fragmented coverage.
4. Weak supply chain and regulatory oversight
Outsourced logistics, minimal regulatory fluency, and basic safety reporting undermine reliability and compliance.
5. Rigid, generic programme models
One-size-fits-all frameworks fail to support cross-border patient movement or complex access challenges.
How Tanner Solves These Challenges
1. Fast, proactive activation
Built to mobilise quickly, operate high-touch, and adapt around your programme from day one.
2. Strategic insight across access, pricing, RWD & labeling
Backed by 20+ years across all access models and deep expertise in rare and high-stakes conditions.
3. Proven global pathways
Established reach in 130+ countries with a team fluent in navigating diverse regulatory and market environments.
4. Integrated, compliant supply and regulatory strength
GDP logistics, specialty handling, robust pharmacovigilance, and deep regulatory fluency across major NRAs.
5. Custom-built programmes aligned to your strategy
Designed around your goals — including support for medical tourism and complex cross-border patient needs.